1. Home
  2. LPA vs ANIX Comparison

LPA vs ANIX Comparison

Compare LPA & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LPA

Logistic Properties of the Americas

HOLD

Current Price

$3.82

Market Cap

93.9M

Sector

N/A

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.79

Market Cap

88.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPA
ANIX
Founded
2013
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.9M
88.8M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
LPA
ANIX
Price
$3.82
$2.79
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
228.4K
174.0K
Earning Date
05-13-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.82
EPS
N/A
N/A
Revenue
N/A
$210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.04
$2.32
52 Week High
$7.51
$5.46

Technical Indicators

Market Signals
Indicator
LPA
ANIX
Relative Strength Index (RSI) 64.78 52.11
Support Level $2.53 $2.38
Resistance Level $3.86 $3.12
Average True Range (ATR) 0.33 0.21
MACD 0.11 0.03
Stochastic Oscillator 70.95 62.31

Price Performance

Historical Comparison
LPA
ANIX

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has four operating segments, based on geographic regions, consisting of Colombia, Peru, Mexico and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: